Evidence & regulatory context
- Mechanism
- Crude botanical extracts; no defined ChEMBL entity. No ClinicalTrials.gov record for Clerodendrum volubile; Irvingia gabonensis appears in weight-management trials unrelated to this indication, so no trial retained.
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatChemical/toxinWistar albinomalen = 7 groups of 7 rats per groupOral400 mg/kg/day of each extract; positive control vitamin C 2…3 hours before each daily trastuzumab dose
Model: Cardiotoxicity induced by repeated daily intraperitoneal trastuzumab 2.25 mg/kg/day for 7 days
Trastuzumab significantly increased serum LDH and cardiac troponin I (p<0.0001), suppressed cardiac SOD, CAT and GST activities and GSH, elevated GPx and MDA, and produced vascular congestion, intraparenchymal haemorrhage and coronary artery microthrombi. Oral pretreatment with 400 mg/kg/day of eit…
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.